Navigation Links
Early Use of MS Drug May Cut Likelihood of Progression
Date:4/19/2012

THURSDAY, April 19 (HealthDay News) -- A new three-year study finds that a multiple sclerosis drug is more likely to prevent patients from progressing to a definite form of MS if it's given early in patients who appear to be ill.

The drug, a form of interferon called "interferon beta-1a," is not available in the United States. It is, however, available in countries in the European Union, Canada and elsewhere.

"While we've known it's beneficial to start MS drugs as soon as possible, this is the first trial to show a benefit of early injections of interferon beta-1a treatment at three years," Dr. Mark Freedman, of the University of Ottawa in Ontario, Canada, said in a news release from the American Academy of Neurology.

The study tracked 517 people who had brain lesions and symptoms -- such as tingling, numbness or balance problems -- that suggested they might have multiple sclerosis.

One-third of the study participants received 44-microgram doses of interferon beta-1a three times a week, one-third received the drug once a week and one-third received an inactive placebo for two years until they showed more signs of having the disease. At that point, they got the dose three times a week.

After two years, 133 people were still taking a placebo. They were then switched to the 44-microgram dose three times a week.

Those who got the drug three times a week for the entire time of the study were less likely to develop what is known as clinically definite MS. Twenty-seven percent of them did so, compared with 28 percent of those who got one dose a week for the entire period, and 41 percent of those who switched mid-stream from the placebo to the actual drug.

Side effects included flu-like symptoms, injection-site reactions and headache.

The findings were released April 19 and will be presented at the American Academy of Neurology's annual meeting, held April 21 to 28 in New Orleans.

"This research adds to a consistent body of evidence suggesting that early treatment for MS is usually better than waiting," Timothy Coetzee, chief research officer at the National MS Society, said in an interview. "Continued research in this area is important so that we can gain a fuller understanding of how therapeutic options actually impact the course of MS and, hopefully, lead to improved quality of life for those diagnosed with MS in the future."

The study, which lasts for five years, is continuing. The research is supported by the pharmaceutical company Merck Serono S.A., of Geneva.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Library of Medicine has more about multiple sclerosis

-- Randy Dotinga

SOURCES: Timothy Coetzee, Ph.D., chief research officer, National Multiple Sclerosis Society; American Academy of Neurology, news release, April 19, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Warren Buffett Has Early Stage Prostate Cancer
2. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
3. Role of Screening, Monitoring in Early Kidney Disease Unclear
4. Brain Tumor Vaccine Shows Promise in Early Trial
5. First contact: Early intervention key in diagnosis and treatment of serious mental illness
6. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
7. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
8. JCI early table of contents for April 9, 2012
9. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
10. Early Study Finds Some Promise for Lung Cancer Vaccine
11. An Early Start for Your Child with Autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early Use of MS Drug May Cut Likelihood of Progression
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology: